Before GLP-1 receptor agonists entered mainstream research, the weight-loss compound landscape was dominated by stimulant-based stacks — ECA combinations, clenbuterol, T3 thyroid analogues, DNP (now considered too dangerous for any research context). The published trial endpoints for those compounds peaked at roughly 5-8% body weight reduction over 12 weeks. GLP-1 research compounds reset the benchmark to 14-24% over 48-72 weeks. This is not a gradual improvement. It is a mechanism shift.
What the old-school stacks actually did
Stimulant-based weight-loss research worked through elevated metabolic rate and central nervous system effects on appetite. The mechanism was peripheral and acute. Subjects burned more calories at rest and ate less under stimulant effect — but the metabolic rate elevation faded within hours, central tolerance developed within weeks, and the cardiovascular load was significant.
- ECA stacks: ~2-4% body weight loss at 8 weeks in research models
- Clenbuterol: ~3-5% weight loss at 4-6 weeks, with rapid receptor desensitisation
- T3 / synthetic thyroid: hard to isolate from concurrent muscle loss
- DNP: dangerous thermal load, not used in modern research
What GLP-1 research compounds do differently
The incretin-class compounds — semaglutide, tirzepatide, retatrutide — act through receptor pathways the body already uses to regulate post-meal satiety. They do not artificially raise metabolic rate or stress cardiovascular systems. They make the brain register fullness for longer, slow gastric emptying so meals last hours instead of an hour, and improve insulin response. The mechanism is endogenous-mimicking, not stimulant-driven.
See our plain-English GLP-1 mechanism article for the full breakdown.
The endpoint comparison
| Approach | Best published endpoint | Mechanism |
|---|---|---|
| ECA stack | ~4% at 8 weeks | Central stimulant + thermogenic |
| Clenbuterol | ~5% at 6 weeks | β2-agonist, thermogenic |
| Semaglutide | 14.9% at 68 weeks | GLP-1 receptor agonism |
| Tirzepatide | 22.5% at 72 weeks | Dual GLP-1/GIP |
| Retatrutide | 24.2% at 48 weeks | Triple GLP-1/GIP/glucagon |
Why the duration matters too
Stimulant stacks lose effect after 4-6 weeks of receptor desensitisation. GLP-1 compounds maintain effect over 18+ months in trial data. The slow trajectory of GLP-1 weight loss is the trade-off: peak velocity is lower, but total magnitude over time is multiples higher.
The safety profile shift
Old-school stacks had real cardiovascular and thermoregulatory risks. Tachycardia, hyperthermia, elevated blood pressure under sustained use. GLP-1 compounds have a different side-effect profile — gastrointestinal in nature, manageable, generally reduces with continued exposure. Cardiovascular outcome trials of semaglutide (SELECT) showed cardiovascular event reduction rather than increase.
What this means for serious research
If you are designing a body-composition research protocol in 2026, the old-school stimulant stack is no longer a credible baseline. The GLP-1 / dual / triple agonist class has replaced it as the reference compound. Comparator arms in modern research use semaglutide or tirzepatide, not ECA.
The handling complexity is different
Old-school weight-loss compounds were oral tablets — simple to administer in research. GLP-1 compounds are lyophilised peptides requiring reconstitution, cold-chain shipping, and proper storage. The infrastructure cost is higher. The trade-off is the magnitude of effect.
Chempeptides supplies HPLC-verified semaglutide, tirzepatide, and retatrutide with batch CoA — see the research catalogue for current availability.
For laboratory research use only. Trial data summarised from published peer-reviewed research.